OmniSonics Medical Technologies
This article was originally published in The Gray Sheet
Executive Summary
Non-thermal tissue removal system will be expanded beyond the current urology/gynecology indications to cardiovascular applications, specifically carotid endartarectomy and vascular stents. President and CEO Robert Rabiner explains at the MassMEDIC conference that the system allows large amounts of tissue to be removed at the time of the procedure. The OmniSonics system uses an 18 Fr catheter, compared to the standard 24 Fr used in competitive products, and the North Reading, Massachusetts-based company says it plans to further reduce the size of the device. The product currently is approved for treatment of benign prostatic hyperplasia and benign uterine disorders